Compare Huntington Ingalls Industries Inc (HII) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Ingalls Industries Inc vs Tempus AI — how do they compare? Huntington Ingalls Industries Inc trades at $265 (market cap $10.27B), while Tempus AI trades at $70.48 (market cap $12.77B). The key difference: Tempus AI is the larger of the two by market cap, and Huntington Ingalls Industries Inc pays a 2.12% dividend while Tempus AI pays none. Which is the better fit depends on your goals — on Pluang, investors hold Huntington Ingalls Industries Inc for 28 Days and Tempus AI for 22 Days on average.
| HII | TEM | |
|---|---|---|
Market Cap | $10.27B | $12.77B |
Volume | 554,386 | 8,980,490 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $453.73 | $99.28 |
52-Week Low | $257.05 | $41.55 |
Typical Hold Time | 28 Days | 22 Days |
Enterprise Value | $13.19B | $13.40B |
Dividend Yield | 2.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HII trades at $260.67, down 1.17% on the day, amid a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $5.27 exceeding expectations. Recent news highlights contract wins, including a $5.1 billion aircraft carrier overhaul and expansion in unmanned systems, supporting a $57.3 billion backlog. Valuation ratios appear reasonable with a P/E of 15.53 and P/S of 0.78.
The outlook is supported by robust defense budgets and contract momentum, but risks include execution on large projects and market sentiment. Analysts are mixed with a 40.7% buy rating and a consensus price target of $363.67, suggesting significant upside potential from current levels if operational performance continues.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Huntington Ingalls Industries Inc
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
